Curing Cancer with Proton Beams

 

Particle accelerators do more than just particle physics research. Suzie Sheehy takes a look at the history and promise of proton therapy: using particle accelerators to fight cancer.

The discovery of X-rays in 1895 was the start of the first breakthrough in modern cancer treatment. Wilhelm Röntgen used a cathode ray tube to generate X-rays. It didn’t take long for the destructive power of these rays to be turned to medicinal benefit. X-rays kill cancer cells through ionization. By stripping electrons from water molecules, the X-ray photons leave a highly chemically reactive wake. The reactive water molecules bind to, and destroy, DNA.

But X-ray beams don’t differentiate between healthy and cancerous cells, so their destructive force is hard to localize to the problem zones alone. One option is to use protons, rather than X-ray photons. Particle accelerators can take protons from inside a Hydrogen atom, form them into high energy beams and more specifically target a tumour.

However, instead of passing through the body like X-ray photons, the protons stop at the tumour, thanks to a phenomenon called the ‘Bragg peak’. By tuning the energy of a proton beam, the dose can be much more carefully controlled.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Advanced Oncotherapy Plc

    Advanced Oncotherapy Update on Distribution Agreement

    Advanced Oncotherapy PLC (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, has today announced that discussions between Yantai Cipu, through its affiliated entity Liquid Harmony, and a major medical equipment and pharmaceutical distribution company

    Hardman & Co

    Advanced Oncotherapy Confidence greatly boosted

    Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology developed originally at the world-renowned CERN. Major technical milestones were achieved in 2017 and the company remains on

    Advanced Oncotherapy Plc

    Hardman & Co: Advanced Oncotherapy PLC (LON:AVO)

    Confidence greatly boosted AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology developed originally at the world-renowned CERN. Major technical milestones were achieved in 2017 and the company remains on track with its

    Advanced Oncotherapy Plc

    “Amazing” recovery of Ashya King

    A young boy with a brain tumour whose parents sparked a Europe-wide manhunt when they whisked him away from hospital has shown the remarkable recovery he’s making. Ashya King revealed to TV presenter Stacey Solomon that

    Advanced Oncotherapy Plc

    Advanced Oncotherapy Director purchased more shares in the company

    Advanced Oncotherapy (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, told DirectorsTalk that yesterday Dr Enrico Vanni, Non-Executive Director of the Company purchased 40,000 ordinary shares of 25 pence in the Company at

    Advanced Oncotherapy Plc

    Advanced Oncotherapy Technological update

    Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it remains on schedule with the development of the first LIGHT system, as per the timetable provided to shareholders on 6

    Hardman & Co

    Advanced Oncotherapy Consolidating market

    Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have been achieved in 2017 and the company remains on

    Advanced Oncotherapy Plc

    Advanced Oncotherapy gets boost from stalwart investor

    How lucky Advanced Oncotherapy PLC (LON:AVO) has been in its investors. Last week the Aim-quoted pioneer of proton beam cancer treatment signed a breakthrough agreement with Yantai CIPU, a Chinese medical technology group, to sell its

    Hardman & Co

    Advanced Oncotherapy Distribution agreement and capital increase

    Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have been achieved in 2017 and the company remains on

    Hardman & Co

    Advanced Oncotherapy Technology advances & stronger balance sheet

    Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an exciting stage with construction of its